ADVM - Adverum Biotechnologies, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.70
+0.19 (+1.65%)
At close: 4:00PM EDT

11.70 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close11.51
Open11.65
Bid11.69 x 1800
Ask11.70 x 800
Day's Range11.64 - 12.10
52 Week Range2.62 - 12.10
Volume582,182
Avg. Volume630,689
Market Cap742.185M
Beta (3Y Monthly)2.56
PE Ratio (TTM)N/A
EPS (TTM)-1.11
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.88
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Adverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Gene Therapy for Wet AMD

    Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was dosed in the second cohort of the ongoing OPTIC phase 1 clinical trial for ADVM-022 for the treatment of wet age-related macular degeneration (wet AMD). Patients are receiving a single intravitreal injection of gene therapy candidate ADVM-022 at a dose of 2 x 10^11 vg/eye. “We believe ADVM-022 has potential to provide sustained therapeutic benefit with a single intravitreal injection to patients living with wet AMD.

  • Adverum Biotechnologies, Inc. (ADVM) Shares March Higher, Can It Continue?
    Zacks25 days ago

    Adverum Biotechnologies, Inc. (ADVM) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Adverum Biotechnologies, Inc. (ADVM).

  • Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN
    Zacks27 days ago

    Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
    Zacks29 days ago

    Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study

    Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.

  • 3 Biotech Stocks That Soared Last Week: Are They Buys?
    Motley Foollast month

    3 Biotech Stocks That Soared Last Week: Are They Buys?

    Can these high-flying biotech stocks keep the momentum going?

  • Barrons.comlast month

    Tallgrass Energy

    ADW Capital Management disclosed on May 13 its approximately 9.7% stake in the interior home-products maker and distributor, equal to 2,514,900 shares of Select Interior’s outstanding stock. Within its latest disclosure, ADW provided a timeline detailing several actions it has taken to spur the home retailer into exploring strategic alternatives for the firm. ADW has now revealed that it dropped its “no vote” campaign after Select Interiors announced that it intends to “initiate a strategic review that includes “operational initiatives, structural alternatives for its assets,” and the potential interest for a merger or sale of the company.

  • All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy
    Zackslast month

    All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy

    Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Benzingalast month

    The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...

  • GlobeNewswirelast month

    Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD

    Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on ADVM-022 for the second cohort in the company’s OPTIC Phase 1 trial for wet age-related macular degeneration (wet AMD), allowing dose escalation to 2 x 10^12 vg/eye.  This dose would be three times higher than the dose of 6 x 10^11 vg/eye evaluated in the first cohort. The dosing of patients in this second cohort is expected to begin in June 2019.

  • Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
    Zackslast month

    Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

    Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.

  • Adverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue Estimates
    Zackslast month

    Adverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue Estimates

    Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 17.86% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Adverum Biotechnologies: 1Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of 23 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • GlobeNewswirelast month

    Adverum Biotechnologies Reports First Quarter 2019 Financial Results and Provides Corporate Update

    MENLO PARK, Calif., May 08, 2019 -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare.

  • Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
    Zackslast month

    Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?

    During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.

  • GlobeNewswire2 months ago

    Adverum Biotechnologies Announces Board Changes

    Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Rekha Hemrajani, M.B.A., James Scopa, J.D., M.B.A., and Mark Lupher, Ph.D. to its Board of Directors, effective immediately.  In addition, Patrick Machado, J.D., an existing member of Adverum’s Board of Directors, has been appointed as Board Chair, effective immediately. Paul Cleveland, who previously served as Board Chair, has retired from the Board of Directors.

  • GlobeNewswire2 months ago

    Adverum Biotechnologies to Present 30-month Preclinical Safety and Expression Data for ADVM-022 Gene Therapy in Wet AMD at the ASGCT 22nd Annual Meeting

    Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new long-term safety and expression data out to 30 months following a single intravitreal injection of ADVM-022 in a preclinical study in wet age-related macular degeneration (wet AMD). The data are being presented today in an oral presentation by Szilard Kiss, M.D., director of clinical research in the Department of Ophthalmology at Weill Cornell Medical College, at the American Society of Gene and Cell Therapy (ASGCT) 22nd Annual Meeting in Washington, D.C.

  • Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks2 months ago

    Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire2 months ago

    Adverum Biotechnologies Presents First Preclinical Data on Dosing Contralateral Eye with ADVM-022 Gene Therapy for Wet AMD at the ARVO 2019 Annual Meeting

    Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, presented today for the first time preclinical data on sequentially dosing a contralateral eye with ADVM-022 gene therapy. The data presented today in a poster session at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting in Vancouver, BC demonstrate that ADVM-022 can be administered safely to the second eye, 2 months after injection in the first eye. “We are excited to show that the second eye injection with ADVM-022 can be performed safely at the time of peak immune response to this therapy injected into the first eye.

  • Is a Beat in the Offing for Humana's (HUM) Q1 Earnings?
    Zacks2 months ago

    Is a Beat in the Offing for Humana's (HUM) Q1 Earnings?

    Humana's (HUM) Q1 earnings are likely to gain on higher membership and a solid Medicare Advantage.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on April ...

  • GlobeNewswire2 months ago

    Adverum Biotechnologies Appoints Thomas Leung as Chief Financial Officer

    Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Thomas Leung as chief financial officer.  Mr. Leung will serve as a member of the Adverum leadership team and will report to Leone Patterson, chief executive officer of Adverum. “We are excited to have Thomas join Adverum as he has significant financial, strategy, and business operations experience,” said Leone Patterson, chief executive officer of Adverum Biotechnologies.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 16) Eidos Therapeutics Inc (NASDAQ: EIDX )(reported fourth ...

  • GlobeNewswire2 months ago

    Adverum Biotechnologies to Present New Preclinical Data on ADVM-022 Gene Therapy for Wet AMD at ASGCT and ARVO

    MENLO PARK, Calif., April 16, 2019 -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare.

  • GlobeNewswire2 months ago

    Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD

    Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today provided a program update on ADVM-022, a novel, single-administration gene therapy being evaluated in the OPTIC Phase 1 clinical trial in patients with wet age-related macular degeneration (wet AMD). The Company has completed enrollment and dosing of patients (n=6) in the first cohort in the OPTIC trial. This was based on a review of the preliminary safety data from the first cohort of patients, which has shown no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) following a single intravitreal injection of ADVM-022 at the initial trial dose of 6 x 10^11 vg/eye.

  • What Kind Of Shareholders Own Adverum Biotechnologies, Inc. (NASDAQ:ADVM)?
    Simply Wall St.2 months ago

    What Kind Of Shareholders Own Adverum Biotechnologies, Inc. (NASDAQ:ADVM)?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Every investor in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) should be aware of the most powerful shareholder groups. L...